This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
c. US$2.5m companion diagnostic test contract win
Full CDMO service contract for development, scale-up, technical transfer, manufacture and full regulatory support
York, U.K. 31 July 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and distributor of high quality and effective rapid tests, announces a new contract win with an expected value of c. US$2.5 million.
The Company has signed a Master Service Agreement ("MSA") with a leading global pharmaceutical company for the development and regulatory approval of a companion diagnostic lateral flow point of care test. The MSA covers the feasibility, optimisation, scale-up, technical transfer and manufacturing of the completed product alongside comprehensive regulatory support. The project is expected to take approximately 24 months via works orders under the MSA which are expected to total c. US$2.5 million.
This contract win underlines the strength of Abingdon Health's CDMO offering which provides customers with comprehensive support to take an "idea through to commercial success". The recent acquisitions of IVDeology and CS Lifesciences, combined with the launch of the Abingdon Analytical Ltd performance evaluation laboratory, has allowed Abingdon to complement its existing lateral flow development and manufacturing capabilities with a full quality and regulatory service offering supported by its 45-strong regulatory team. The significant benefits of having one outsourced partner covering all aspects of product development is resonating well with customers as evidenced by this new contract win.
Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers.
Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented : "This contract award demonstrates the value of our comprehensive CDMO platform. We deliver end-to-end diagnostic solutions from initial concept through to market launch, and this win reflects strong customer confidence in our integrated approach. Our companion diagnostics expertise has become a key competitive advantage, particularly our ability to coordinate both diagnostic and the client's therapeutic development pathways. This expertise, combined with our regulatory knowledge, provides clients with seamless project management and reduced complexity."
Enquiries:
| Abingdon Health plc |
|||
| Chris Hand, Executive Chairman
|
Via Walbrook PR |
||
| T om Hayes, CFO
|
|
||
| |
|
||
| Zeus (Sole Broker and Nominated Adviser) |
Tel: +44 (0)20 3829 5000 |
||
| Antonio Bossi / Jacob Walker (Corporate Finance) |
|
||
| Fraser Marshall (Corporate Broking)
|
|
||
| |
|
||
| Walbrook PR (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com |
||
| Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
||
| |
|
||
About Abingdon Health plc
Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.
The Company's CDMO division offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health's CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".
Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology , provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.
Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York, England.
For more information visit: www.abingdonhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.